SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Biomaven5/10/2016 5:33:53 PM
4 Recommendations

Recommended By
glass 0.5 full
pgo-neil
sjemmeri
tktom

  Read Replies (2) of 4474
 
Very nice deal with Incyte.

It's hard to break down how much they paid for the infrastructure vs. paying for Iclusig, but it is important to remember that they only bought under 15% of the drug. Assume Europe is about 25% of the value of the drug, and then they bought about half of that (maybe less) given the very high royalty rate. Plus Ariad (via a buyout) gets a call option which is certainly worth something. If the upfront $140m was all for Iclusig (hard to know) that would easily value it at over $1 billion if my back-of-the-envelope calculation is about right.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News